Gross Profit Comparison: Pfizer Inc. and Alkermes plc Trends

Gross Profit Trends: Pfizer Inc. vs. Alkermes plc

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis highlights the gross profit trajectories of two key players: Pfizer Inc. and Alkermes plc, from 2014 to 2023. Over this period, Pfizer consistently outperformed Alkermes, with its gross profit peaking in 2022 at approximately 66 billion USD, a staggering 3700% higher than Alkermes' peak in the same year. However, Alkermes showed remarkable growth, with its gross profit increasing by over 700% from 2014 to 2023. Notably, Pfizer experienced a significant dip in 2023, dropping to around 29 billion USD, while Alkermes reached its highest point at 1.4 billion USD. This data underscores the dynamic nature of the pharmaceutical sector, where even industry giants face fluctuations, and smaller companies can achieve substantial growth.